Australia
Kazia Therapeutics has a laser-like focus on adding value: Corporate Connect Research
Kazia Therapeutics Ltd (ASX:KZA) is making steady progress in advancing its investigational new drug, paxalisib, executing an agreement last week to participate in the GBM AGILE pivotal study in glioblastoma.
GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment) is an international platform study that has been established specifically to facilitate the approval of new medicines for glioblastoma, an aggressive type of cancer that can occur in the brain or spinal cord.
The study is set to move into an operational phase with recruitment of patients to the paxalisib arm expected to begin in the first quarter of 2021.
Corporate Connect Research has initiated coverage on Kazia with a 12-month price target of $2.05 (current share price: 85 cents).
The following is an extract from Corporate Connect’s initiation report:
Since August 1st, Kazia Therapeutics has announced US Food & Drug Administration fast track status for one program & orphan drug and rare paediatric dise..
-
Tech8 months ago
Search engine startup asks users to be the customer, not the product
-
Europe2 months ago
Covid: Flights shut down as EU discusses UK virus threat
-
Health2 months ago
Spain ‘to register’ those who refuse to have Covid-19 vaccine
-
Europe1 month ago
Post-Brexit trade: Is red tape chaos just ‘teething trouble’ as the UK government argues?
-
Sports4 years ago
Boxing continues to knock itself out with bewildering, incorrect decisions
-
latest news9 months ago
Creepy technologies invade European post-pandemic workplaces
-
Australia2 months ago
Covid: Brisbane to enter three-day lockdown over single infection
-
latest news7 months ago
Lessons for Africa from devastating Mauritius oil spill